G. Parry

Can we eliminate placebo in ALS clinical trials?

J. Murphy, C. Armon, M. Ross, 2003, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

Quantitative sensory testing Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

J. Ochoa, D. Cornblath, M. Giuliani, 2003 .

Relationship of the Tufts Quantitative Neuromuscular Exam (TQNE) and the Sickness Impact Profile (SIP) in measuring progression of ALS

J. Petajan, R. Barohn, C. Armon, 1996, Neurology.

Conduction block in clinical practice

W. Brown, J. Albers, J. Daube, 1991, Muscle & nerve.

Derivation and validation of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy

L. Magder, R. Barohn, C. Koski, 2009, Journal of the Neurological Sciences.

A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group.

R. Barohn, R. Miller, C. Armon, 1996, Annals of neurology.

Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis

G. Parry, M. Bromberg, J. Petajan, 1996, Neurology.

Reliability of maximal voluntary isometric contraction testing in a multicenter study of patients with amyotrophic lateral sclerosis

J. Petajan, Robert G. Miller, M. Mendoza, 1997, Muscle & nerve.

Quantitative sensory testing

J C Arezzo, J. Ochoa, J. Arezzo, 2003, Neurology.

Toward earlier diagnosis of amyotrophic lateral sclerosis

R. Barohn, R. Miller, C. Armon, 1998, Neurology.

Quantitative sensory testing Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

J. Ochoa, D. Cornblath, M. Giuliani, 2003 .

Limitations of quantitative sensory testing when patients are biased toward a bad outcome.

J. Ochoa, D. Yarnitsky, G. Parry, 1999, Neurology.